Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
15.66
+0.92 (+6.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus Inc
< Previous
1
2
3
4
Next >
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
January 18, 2023
From
Evolus
Via
Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
December 08, 2022
From
Evolus
Via
Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in November Conferences
November 02, 2022
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
October 04, 2022
From
Evolus
Via
Business Wire
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
September 21, 2022
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants for New Chief Financial Officer
September 06, 2022
From
Evolus
Via
Business Wire
Evolus Appoints Sandra Beaver as Chief Financial Officer
August 30, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
From
Evolus
Via
Business Wire
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
August 24, 2022
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2022 Results and Provides Business Update
August 02, 2022
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter 2022 Results and Provide Business Update
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
July 19, 2022
From
Evolus
Via
Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
July 12, 2022
From
Evolus
Via
Business Wire
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
June 02, 2022
From
Evolus
Via
Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
May 18, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 11, 2022
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2022 Results and Provides Business Update
May 10, 2022
From
Evolus
Via
Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
April 26, 2022
From
Evolus
Via
Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
March 31, 2022
From
Evolus
Via
Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 29, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
February 17, 2022
From
Evolus
Via
Business Wire
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
February 08, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference
February 02, 2022
From
Evolus, Inc.
Via
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
January 26, 2022
From
Evolus, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.